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Abstract
Background: Injection drug users (IDUs) face numerous obstacles to receiving optimal HIV care, and have been
shown to underutilize antiretroviral therapy (ART). We sought to estimate the degree to which providers of HIV
care defer initiation of ART because of injection drug use and to identify clinic and provider-level factors associated
with resistance to prescribing ART to IDUs.
Methods: We administered an Internet-based survey to 662 regular prescribers of ART in the United States and
Canada. Questionnaire items assessed characteristics of providers’ personal demographics and training, site of
clinical practice and attitudes about drug use. Respondents then rated whether they would likely prescribe or defer
ART for hypothetical patients in a series of scenarios involving varying levels of drug use and HIV disease stage.
Results: Survey responses were received from 43% of providers invited by email and direct mail, and 8.5% of
providers invited by direct mail only. Overall, 24.2% of providers reported that they would defer ART for an HIV-
infected patient with a CD4+ cell count of 200 cells/mm
3 if the patient actively injected drugs, and 52.4% would
defer ART if the patient injected daily. Physicians were more likely than non-physician providers to defer ART if a
patient injected drugs (adjusted odds ratio 2.6, 95% CI 1.4-4.9). Other predictors of deferring ART for active IDUs
were having fewer years of experience in HIV care, regularly caring for fewer than 20 HIV-infected patients, and
working at a clinic serving a population with low prevalence of injection drug use. Likelihood of deferring ART was
directly proportional to both CD4+ cell count and increased frequency of injecting.
Conclusions: Many providers of HIV care defer initiation of antiretroviral therapy for patients who inject drugs,
even in the setting of advanced immunologic suppression. Providers with more experience of treating HIV, those
in high injection drug use prevalence areas and non-physician providers may be more willing to prescribe ART
despite on-going injection drug use. Because of limitations, including low response rate and use of a convenience
sample, these findings may not be generalizable to all HIV care providers in North America.
Background
Injection drug use continues to account for a significant
proportion of the HIV burden in the United States and
Canada [1,2]. In addition to having increased risk of
HIV acquisition and transmission, injection drug users
(IDUs) tend to have more limited engagement in HIV
care and treatment. Data from some clinical and com-
munity-based observational cohorts have indicated that
active IDUs have inferior virologic [3,4] and
immunologic [5,6] responses to antiretroviral therapy
(ART) compared with former IDUs and non-drug using
patients.
Despite this, we and others have observed survival
benefits of ART among IDUs with advanced HIV/AIDS
that approaches that observed in other risk groups [7,8].
Studies in other contexts with universal access to ART
have demonstrated similar mortality and rates of antire-
troviral resistance among IDUs and non-IDUs [9,10],
suggesting that the availability of interventions to sup-
port adherence and address co-morbid substance abuse
may effectively eliminate the ART-related disparities
observed in other settings [11].
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between injecting drugs and poor HIV treatment out-
comes include delayed diagnosis and treatment initiation
[12-14], poor retention in outpatient care [15,16], and
inadequate medication adherence [5,17]. Additional
individual-level correlates of delayed entrance or disen-
gagement from care are older age, black race, and dis-
trust of the medical care system [18,19]. While
individual-level and behavioural variables have been the
focus of most previous research, some authors have pro-
posed expanding the paradigm used for studying sub-
optimal HIV care to encompass social and structural
factors, such as stigmatization, drug policies and health
care delivery considerations [20,21]. In a nationally
representative study, drug-injecting patients whose HIV
providers had negative attitudes toward IDUs were sig-
nificantly less likely to receive ART [22]. IDUs who have
favourable perceptions of the relationship with their
HIV providers tend to have more appropriate ART utili-
zation and better virologic response [23,24]. Beyond
individual providers, contextual factors that have been
associated with improved treatment outcomes include
aggregate HIV care experience and clinic site specializa-
tion [25-27].
Whether underutilization of ART by IDUs is driven to
a greater extent by providers’ decisions to not recom-
mend treatment or by patients’ refusal is unclear,
although both scenarios are known to occur [28]. The
practice of withholding ART solely on the basis of injec-
tion drug use runs counter to clinical guidelines issued
by the World Health Organization, which explicitly state
that drug injecting should not disqualify patients from
ART eligibility, and that addiction treatment should not
be required before ART initiation [29]. We investigated
this issue by evaluating North American HIV providers’
willingness to initiate ART in the context of active injec-
tion drug use by their patients. Toward the goal of
informing future provider-level interventions to reduce
health disparities for HIV-infected drug users, we sought
to identify characteristics that distinguish providers who
are likely to defer for ART to medically eligible, active
IDUs from those who would be likely to prescribe ART
despite on-going injecting.
Participant recruitment
Between October 2009 and May 2010, we recruited
health care practitioners who self-identified as regular
providers of HIV care to complete an anonymous, 120-
item, Internet-based survey. Because one aim of this
study was to investigate barriers to optimal HIV care for
a cohort of injection drug users in Baltimore, Maryland,
USA, we specifically targeted HIV providers in the Balti-
more metropolitan area who were identified through
local provider databases and clinic staff directories.
These Baltimore-based HIV providers were individually
invited to participate with up to two mailed letters and
three reminders via email, which contained an Internet
address and password needed to access the survey.
The sampling frame was then broadened to include
providers throughout North America, who were
recruited using three complementary approaches: 1) a
database of antiretroviral medication prescribers in the
state of Maryland and the Washington D.C. metropoli-
tan area identified through the American Medical Asso-
ciation Masterfile; 2) venue-based recruitment at
national and international HIV conferences; and 3) an
email list of subscribers to an electronic HIV clinical
care resource. Providers in Maryland and the Washing-
ton D.C. area were sent mailed invitations with instruc-
tions for accessing the web-based survey as email
addresses were not available.
Venue-based sampling occurred at: annual meetings of
the Infectious Diseases Society of America in Philadel-
phia, PA; the International Antiviral Society-USA in
New York, NY; and a clinical HIV care conference
hosted by the Johns Hopkins HIV Service in Baltimore.
An advertisement inviting eligible providers to complete
the survey was circulated to subscribers of an electronic
HIV clinical care guide, who could access the survey
through a link contained in an email message. Surveys
were created and administered using SurveyMonkey
(Portland, Oregon). The Johns Hopkins Bloomberg
School of Public Health Institutional Review Board
reviewed the study protocol and granted it exempt
status.
Response rate
Of 368 providers practicing in Baltimore who were indi-
vidually invited to participate, 157 (43%) completed sur-
veys. Basic demographic data were available for 168
(80%) of the 211 Baltimore-based non-responders. Com-
pared with participating providers, non-responders were
more likely to be male (66% vs. 44%, p < 0.001) and
have an MD or DO degree (92% vs. 78%, p = 0.002) and
were less likely to be trained in infectious diseases (8%
vs. 54%, p < 0.001). Non-Baltimore providers contacted
by mail had a response rate of 8.5%. As convenience
sampling was utilized to recruit survey participants at
professional conferences and via the online list-serve, we
could not ascertain response rates relevant to the
broader recruitment strategies.
Compared with Baltimore-based providers, those
recruited via conferences and the HIV list-serve were
more likely to be male (57% vs. 40%, p < 0.001), to have
specialty training in infect i o u sd i s e a s e s( 7 6 %v s .5 6 % ,p
< 0.001), to care for 50 or more HIV-infected partici-
pants (58% vs. 44%, p < 0.001), and were less likely to
work at a clinic serving a patient population with a high
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26%, p < 0.001)
Survey design
This cross-sectional survey assessed demographics and
professional characteristics, such as degree type, speciali-
zation, years of clinical experience and volume of patient
care activities. A series of questions addressed character-
istics of the provider’s primary practice site, including its
geographic location (urban vs. suburban vs. rural),
whether it provides mostly primary care or specialty
care, and whether it is affiliated with an academic insti-
tution. Providers were asked to estimate the proportion
of patients seen in their practices who were HIV-
infected, had used injection drugs, were underrepre-
sented minorities, and lacked health insurance. Other
questions addressed the availability of certain services at
the primary practice site, including HIV testing, social
work services, substance abuse treatment and transpor-
tation assistance.
Provider knowledge, attitudes and beliefs related to
injection drug use were assessed based on the degree to
which the respondent agreed or disagreed (using a 5-
point Likert scale) with a series of statements designed
to assess negative or prejudicial attitudes toward IDUs.
The statements were drafted by a committee of HIV
clinicians and researchers and pilot tested on 15 provi-
ders who treat patients in an urban, university-affiliated
HIV clinic. Revision and refinement resulted in nine
items incorporated into the final survey. Examples
include: “I feel uncomfortable talking to my patients
about their injection drug use practices"; and “HIV-
infected IDUs have themselves to blame for their ill-
ness”. The full text of all questionnaire items is available
in the Additional file 1.
Deferral of ART was assessed by asking respondents
to self-rate the likelihood of prescribing ART to a series
of hypothetical patients. The range of patient scenarios
included a patient with no drug use history, a former
IDU who had been abstinent for three months, a cur-
rent IDU who injects several times per month, and a
daily injector. Within each of these four categories of
drug use, respondents were further asked to rate the
likelihood of deferring ART if the patient in question
had a CD4+ cell count of 200 cells/mm
3, 350 cells/mm
3
or 500 cells/mm
3.
Statistical analysis
Descriptive statistics related to demographic, provider
and clinic characteristics were analyzed using Chi-
squared and Fisher’s exact tests for categorical data.
After sensitivity analyses of potential categorizations,
Likert scale variables related to provider attitudes and
beliefs were categorized into “agree” (strongly agree and
agree) and “do not agree” (neutral, disagree or strongly
disagree). Attitude and belief items that showed signifi-
cant bivariate association with deferral of ART (p value
for Chi-squared test less than 0.10) were included in
subsequent analyses.
The main, binary outcome of interest in this study was
a provider report that one would probably defer ART
for patient with a CD4+ cell count equal to 200 cell/
mm
3 if he or she reported any active (i.e., daily or occa-
sional) injection drug use. This approach was chosen
because there is near-universal consensus that ART
initiation is indicated for patients with this degree of
immunosuppression, regardless of symptoms, in both
resource-rich and resource-limited settings [30,31]. A
decision to defer ART in this context, therefore, likely
indicates that a provider believes active injecting pre-
cludes effective ART. Logistic regression models were
constructed using forward and backward stepwise
approaches to identify variables that were independently
associated with deferring ART in the setting of any
active IDU. Because revised guidelines regarding when
to start antiretroviral therapy were published by the US
Department of Health and Human Services (DHHS)
during the study period [32], we included a covariate
indicating whether respondents completed the survey
prior to or after 1 December 2009, when the guidelines
were released.
In secondary analyses, we repeated these model-build-
ing steps for the separate outcomes of ART deferral for
drug injecting patients with CD4+ cell counts of 350
cells/mm
3 and 500 cells/mm
3.W en e x tc o m p a r e dt h e
proportion of providers who would defer ART within
each of the three strata of CD4+ cell count and the four
strata of drug-injecting status, allowing examination of
prescribing behaviour across 12 scenarios characterized
by varying drug use and disease severity. Finally, we
used these data to characterize providers whose decision
to defer differed depending on intensity of injecting (i.e.,
daily vs. occasionally). Statistical analyses were per-
formed using STATA Version 11 (StataCorp, College
Station, TX).
Results
Characteristics of the study population
Overall, 662 providers from North America responded
to the survey: 94.7% reported practicing in the US and
5.3% were from Canada. US-based respondents prac-
ticed in 39 different states, with the greatest number
coming from Maryland (26%), New York (12%) and
Pennsylvania (7%). Demographic, professional and
clinical site characteristics are displayed in Table 1.
The median age was 43 (IQR 35-52) and the median
number of years providing HIV care was 10 years
(IQR 4-18).
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received specialty training in infectious diseases (70.7%),
and reported that more than 75% of their professional
activity entailed providing direct patient care (61%). The
majority of providers (81.7%) reported regularly provid-
ing care for at least 20 HIV-infected patients; 35%
reported caring for more than 100 HIV-infected patients
regularly. Compared with physician respondents, non-
physician providers (mostly nurse practitioners and phy-
sician assistants) were older (p <0 . 0 0 1 ) ,h a db e e np r a c -
ticing longer (p =0 . 0 0 2 ) ,a n dw e r em o r el i k e l yt o
regularly care for more than 100 HIV-infected patients
(p = 0.02) or to practice in a setting with a high density
of IDUs (p = 0.004).
Most providers characterized their primary practice
location as urban (76.6%). Clinic sites were more com-
monly described as specialty clinics (43%) than primary
care (23%) or hospital-based clinics (34%). Fewer than
half of providers (44.1%) indicated that their clinic was
affiliated with an academic institution. More than half of
providers (54%) estimated that the prevalence of injec-
tion drug use among patients served by their primary
Table 1 Provider and practice site characteristics (n = 662)
Provider characteristics No. (%) Clinical site characteristics No. (%)
Degree Practice location
RN/NP/PA 126 (20.5) Urban 497 (76.6)
MD/DO 488 (79.5) Suburban 115 (17.7)
Gender Rural 37 (5.7)
Female 321 (48.8) Referral level
Male 337 (51.2) Primary care 149 (23.0)
Age Specialty care 279 (43.0)
< 35 134 (20.2) Hospital based 221 (34.0)
35-50 307 (46.4) Academic affiliation
50+ 230 (33.4) No 370 (55.9)
Race/ethnicity Yes 292 (44.1)
White 409 (61.8) Proportion of patients who are uninsured
Asian 123 (18.6) < 10% 231 (35.6)
Hispanic 42 (6.3) 10-25% 153 (23.6)
Black 49 (7.4) 25%-75% 191 (29.5)
Other/decline 39 (6.0) More than 75% 73 (11.3)
Specialization Proportion of patients who are IDU
Infectious diseases 435 (70.7) < 10% 350 (54.0)
Primary care 122 (19.8) 10-25% 232 (35.8)
Other 58 (9.4) More than 25% 66 (10.2)
Years caring for HIV pts. Substance abuse treatment on site
< 5y 178 (26.9) No 365 (55.1)
5-10y 147 (22.2) Yes 297 (44.9)
10-20y 188 (28.4) Mental health services on site
> 20y 148 (22.4) No 227 (34.3)
Number of HIV patients Yes 435 (65.7)
cared for regularly
< 20 121 (18.3) Recruitment method No. (%)
20-50 192 (29.0) Direct mail and/or email 184 (27.8)
50-100 117 (17.7) HIV conferences 251 (37.9)
> 100 232 (35.0) HIV list-serve 227 (34.3)
Amount of workload comprised of clinical care
Less than 25% 141 (21.3)
About half 117 (17.7)
More than 75% 404 (61.0)
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reported that their local prevalence of injection drug use
exceeded 25%.
Responses to four survey items assessing attitudes and
beliefs that showed a significant bivariate association
with deferral of ART are listed in Table 2. A majority of
providers disagreed or felt neutral about the statements,
“Health care providers have little influence over patients’
IDU practices” and “I feel uncomfortable talking to my
patients about their IDU practices”. A small minority of
providers agreed with the statement, “Providers are not
professionally obligated to care for IDUs with HIV
infection”. Approximately half of providers agreed with
the statement, “Even former IDUs have difficulty adher-
ing to HAART”.
Provider and clinic-level correlates of deferring ART
Table 3 displays unadjusted and adjusted odds ratios
describing provider characteristics and clinic-level fac-
tors associated with deferring ART for active IDUs with
CD4+ counts of 200 cells/mm
3. Overall, 24.2% of provi-
ders would defer ART for a patient who occasionally
injected drugs, while 52.4% would defer ART for daily
injection drug use. Multivariate analysis indicated that
physicians were significantly more likely than non-physi-
cian providers to defer ART for active IDUs (adjusted
OR 2.6; 95% CI 1.4-4.9). Providers with greater HIV
care experience and a larger panel of HIV-infected
patients were significantlyl e s sl i k e l yt od e f e rA R Ta t
this level, although providers who reported that greater
than 75% of their workload was direct patient care
(rather than research, teaching or administration) were
significantly more likely to defer ART. Furthermore, the
subset of providers having both the highest clinical
workload but the fewest number of regular HIV patients
(< 20) were particularly likely to defer therapy, with 40%
reporting they would defer ART in this setting (data not
shown).
Compared with low injection drug use prevalence set-
tings, providers practicing at clinics serving communities
with high injection drug use prevalence (< 25%) were
60% less likely to defer therapy because of active inject-
ing (OR 0.4; 0.2-1.0). Of the provider attitude and belief
question items, agreeing that “Providers are not profes-
sionally obligated to care for IDUs with HIV” was asso-
ciated with a five-fold increased likelihood of deferring
ART (OR 5.1; 2.8-9.3). Providers who agreed that “Even
former drug users have difficulty adhering to HAART”
were 60% less likely to defer ART (OR 0.4; 0.2-1.0) com-
pared with providers who disagreed with or felt neutral
about this statement.
Similar but non-identical provider and clinic charac-
teristics were found to be predictive of deferring ART
for drug injectors with CD4+ cell levels of 350 cells/
mm
3 and 500 cells/mm
3. Considering active IDUs with
CD4+ counts of 350 cells/mm
3, Physicians were again
more likely to defer ART (OR 1.9; 1.2-2.9), as were pro-
viders who spend more than 75% of their time in clini-
cal care (OR 2.0; 1.3-3.1). Working at a clinical site with
substance abuse treatment services available was asso-
ciated with decreased odds of ART deferral, although no
association with community prevalence of injection drug
use was observed at the 350 cells/mm
3 CD4+ level. In
the scenario of a patient with a CD4+ count of 500
cells/mm
3, the majority of providers (61.5%) indicated
that they would defer therapy regardless of the presence
of injection drug use. In this setting, physicians were no
more likely than non-physician providers to defer ART
because of active injecting. Infectious disease-trained
physicians were more likely to defer therapy than provi-
ders without specialty training (OR 2.2; 1.4-3.46), an
association not observed at lower CD4+ counts. Provi-
ders who agreed with the statement, “I feel uncomforta-
ble talking to my patients about their IDU practices”,
were significantly less likely to defer ART for a patient
with CD4+ count of 500 cells/mm
3 and active injection
drug use (OR 0.5; 0.3-1.0).
In sub-group analyses, similar associations of provider
characteristics with ART deferral were observed when
data were restricted to Baltimore area providers only
and to those identified through venue-based or to list-
serve recruitment (data not shown). Overall rates of
Table 2 Beliefs and attitudes towards IDUs among survey respondents (n = 662)
Strongly disagree Disagree Neutral Agree Strongly agree
“Even former IDUs have difficulty adhering to HAART”
66 (10.2) 253 (39.0) 120 (18.5) 186 (28.7) 24 (3.7)
“Health care providers have little influence over patients’ IDU practices”
74 (11.4) 341 (52.5) 124 (19.1) 95 (14.6) 15 (2.3)
“I feel uncomfortable talking to my patients about their IDU practices”
258 (39.8) 293 (45.2) 23 (3.5) 53 (8.2) 22 (3.4)
“Providers are not professionally obligated to care for IDUs with HIV”
292 (45.0) 241 (37.1) 68 (10.5) 37 (5.7) 11 (1.7)
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Likely to defer ART at CD4+ 200 cells/mm
3
Provider characteristics No. (%) Unadjusted OR Adjusted OR*
Gender
Female 63 (19.6) -
Male 88 (26.11) 1.45 (1.00-2.09)
Age
< 35 33 (24.6) -
35-50 89 (29.0) 1.25 (0.79-1.98)
50+ 31 (14.1) 0.5 (0.29-0.87)
Degree
RN/NP/PA 14 (11.1) - -
MD/DO 125 (25.6) 2.75 (1.52-4.98) 2.61 (1.39-4.92)
Infectious disease specialization
No 41 (22.8) -
Yes 101 (23.2) 1.03 (0.68-1.55)
Years caring for HIV pts.
Per 5y increase 0.83 (0.74-0.93) 0.84 (0.73-0.95)
Number of HIV patients cared for regularly
< 20 43 (35.5) - -
20-50 45 (23.4) 0.56 (0.34-0.92) 0.59 (0.33-1.05)
50-100 25 (21.4) 0.49 (0.27-0.88) 0.67 (0.35-1.29)
> 100 40 (17.2) 0.38 (0.23-0.63) 0.45 (0.25-0.83)
Amount of workload comprised of clinical care
less than 25% 24 (17.0) - -
about half 22 (18.8) 1.13 (0.60-2.14) 1.24 (0.57-2.73)
more than 75% 107 (26.5) 1.76 (1.07-2.87) 2.45 (1.35-4.45)
Clinical site characteristics
Substance abuse treatment on site
No 97 (26.6) -
Yes 56 (18.9) 0.64 (0.44-0.93)
Proportion of patients who are IDU
< 10% 91 (26.2) - -
10-25% 48 (20.8) 0.74 (0.50-1.1) 0.83 (0.52-1.32)
More than 25% 8 (12.1) 0.39 (0.18-0.85) 0.41 (0.16-1.03)
Provider attitudes
“Even former IDUs have difficulty adhering to HAART”
Disagree or neutral 101 (30.6) - -
Agree 47 (14.7) 0.39 (0.27-0.58) 0.42 (0.28-0.65)
“Health care providers have little influence over patients’ IDU practices”
Disagree or neutral 114 (21.1) -
Agree 34 (30.9) 1.67 (1.06-2.63)
“I feel uncomfortable talking to my patients about their IDU practices”
Disagree or neutral 130 (22.6) -
Agree 18 (24.0) 1.08 (0.61-1.90)
“Providers are not professionally obligated to care for IDUs with HIV”
Disagree or neutral 121 (20.1) - -
Agree 27 (56.2) 5.1 (2.79-9.33) 4.79 (2.48-9.23)
*Adjusted for all other variables in the model
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the date of survey completion was before or after publi-
cation of the 2009 DHHS Antiretroviral Treatment
Guidelines. Comparing respondents after 12 December
2009 to those before this date, smaller proportions of
providers would defer ART for active IDUs with CD4+
counts of 350 cells/mm
3 (43.4% and 52.2%, respectively,
p = 0.03) and 500 cells/mm
3 (81.9% and 87.5%, p =
0.05). No difference in ART deferral was observed
according to date of survey response for the CD4+ level
of 200 cells/mm
3 (22% vs. 25%, p = 0.3). Including date
of survey response as a covariate did not change the
associations described for any of the three multivariate
models.
Influences of CD4+ level and intensity of drug injecting
Figure 1 illustrates the percentage of providers who
reported that they would defer ART for patients at three
CD4+ levels (200, 350 and 500 cells/mm
3)a n di nf o u r
different drug use scenarios (no injecting history, former
injecting but abstinent for three months, active but less
than daily injecting, and daily injecting). Within each of
the three CD4+ count strata, we observed a stepwise
increase in the proportion likely to defer ART as inten-
sity of injection drug use increased. As expected, vir-
tually all providers would prescribe ART to a typical
patient with no substance abuse history and a CD4+
count of 200 cells/mm
3. Nearly one-fourth of providers
(24.2%), however, would defer ART if an otherwise simi-
lar patient reported occasional injection drug use, and
more than half (52.4%) would withhold therapy if a
patient injected daily. Large and statistically significant
differences in likely prescribing were observed between
the former injecting and occasional injecting scenarios
within each CD4+ count category (p < 0.001 for each
comparison). There were further large differences in
likely prescribing practices between the occasional
injecting and daily injecting conditions within each CD4
+ count category (p < 0.001).
Whether providers viewed ART eligibility differently
for patients who never injected drugs and former IDUs
(in remission for three months) appeared to depend on
the degree of immunosuppression. At CD4+ counts of
200 and 350 cells/mm
3, providers were similarly unlikely
to defer ART for patients without a history of injection
drug use and for those with former injection drug use
who had been abstinent for three months. Providers
were, however, slightly more likely to defer therapy for
former IDUs than for patients with no history of injec-
tion drug use if the CD4+ count was 500 cells/mm
3
(67.2% vs. 61.5% would defer ART, p = 0.03).
Discordant prescribing for occasional versus daily IDUs
Next, we aimed to characterize providers who indicated
that their decision to prescribe ART to an active IDU
would differ depending on the intensity of drug use
(daily vs. occasional injecting). While a slight majority of
providers (347 of 662, 52%) indicated that they would
defer ART for IDUs with daily injection and a CD4+
count of 200 cells/mm
3, most of these providers (194 of
347, 56%) alternatively reported they would prescribe
ART to a similar patient with intermittent injecting.
Compared with those who deferred ART with any active
injecting, providers willing to prescribe in the setting of
occasional injecting were more likely to be non-physi-
cian providers, to have greater HIV care experience, to
work in an academic setting, and to practice at a site
that serves a higher density of IDUs and provides on-
site services for substance abuse treatment.
Discussion
In this cross-sectional survey of providers of regular
HIV care, we found that active injection drug use
appears to be a major factor in the decision to adminis-
ter antiretroviral therapy. While virtually all providers
studied indicated that they would prescribe ART for a
typical patient with CD4+ cell count of 200 cells/mm
3,
nearly one in four providers said that they would defer
treatment if a patient reported any injection drug use,
and more than half would defer therapy if a patient
reported daily injection drug use. Relative differences in
ART deferral for drug injectors versus non-injectors
were even more pronounced at higher CD4+ counts
when initiation of ART is generally considered to be
less urgent.
A prominent finding in the multivariate models for
the lower CD4+ count categories was that physicians
were more likely to defer ART because of injection drug
use than non-physician providers. This is in contrast to
findings of a previous HIV provider survey by Loughlin
Figure 1 Percentage of providers who would defer ART by
CD4+ count and injection drug use status.
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more likely than physicians to be resistant to prescribing
ART to IDUs [33]. In the prior study, non-physicians
had less clinical HIV experience than their physician
counterparts, and were more likely to work in a setting
with a higher prevalence of drug use. By contrast, the
non-physician providers surveyed in the present study
had been in practice longer and tended to see a higher
volume of HIV-infected patients. Comparison of the two
studies may suggest that clinician experience and prac-
tice setting, rather than degree type, are important cor-
relates of ART-prescribing behaviour. While the
potential for unmeasured confounding exists, adjust-
ment for size of HIV-infected patient panel and injec-
tion drug use prevalence did not eliminate the observed
association between degree type and likelihood of defer-
ring ART. Further study that incorporates qualitative
interviews with providers may lead to better understand-
ing of this discrepancy in view of the complex issues
that providers encounter when deciding to initiate ART.
Previous research has indicated that patients who
receive care from providers with expertise in HIV medi-
cine are more likely to receive appropriate combination
ART [34-37], and in the “pre-HAART era”, to have had
improved survival [25,26]. In our study, specialty train-
ing in infectious diseases was not associated with ART
deferral at low CD4+ counts, although those with infec-
tious diseases training were more likely to defer ART at
aC D 4 +c o u n to f5 0 0c e l l s / m m
3 if a patient injected
drugs. Having a smaller volume of HIV-infected patients
in one’s clinic panel was associated with deferring ART
for active IDUs. Deferring ART was also more common
among providers who provide direct patient care for
more than 75% of their professional effort.
Taken together, these findings suggest that busy, full-
time clinicians with a relatively small panel of HIV-
infected patients may be particularly likely to under-pre-
scribe ART because of injection drug use. In our study,
the subset of providers engaged in greater than 75% of
patient care but who regularly care for fewer than 20
patients were those most likely to defer ART for IDUs
with advanced HIV, with 40% reporting that they would
defer ART at a CD4+ count of 200 cells/mm
3. Our find-
ings are thus in agreement with previous authors who
h a v es u g g e s t e dt h a tp r o v i s i o no fr e g u l a rc a r et oa tl e a s t
20 to 25 HIV-infected patients is an appropriate mini-
mum standard to be considered to be a qualified HIV
provider [38].
Provider judgement about likely adherence is an
important factor in the decision to prescribe ART [39].
We correspondingly hypothesized that providers who
more strongly believe that IDUs have poor adherence
would be more likely to defer ART in the setting of
active injecting. Unexpectedly, we found that providers
who agreed or strongly agreed with the statement, “Even
former IDUs have difficulty adhering to HAART”, were
significantly less likely to defer ART for IDUs with low
CD4+ counts. A possible explanation for this surprising
result is that rather than identifying providers who are
highly sceptical of the effectiveness of ART for drug
users and would be therefore reluctant to recommend
it, the survey item distinguished providers who recog-
nize the chronic, relapsing nature of drug dependence.
Providers who accept the chronic disease paradigm of
drug dependence may have superior knowledge of stra-
tegies to manage addiction, and therefore have greater
optimism that HIV and subst a n c ea b u s ec a nb ee f f e c -
tively co-managed.
There are several limitations to our study that may
restrict its generalizability. We utilized a convenience
sampling technique, taking advantage of venues that
attract large numbers of HIV providers in order to
recruit participants from diverse backgrounds. Providers
who agreed to participate are not representative of all
attendees of HIV-related conferences, nor are confer-
ence attendees and list-serve subscribers representative
of all HIV providers who provide care to IDUs in North
America. We attempted to mitigate this source of bias
by collecting detailed demographic and professional data
from participants, and by recruiting a sufficiently large
sample size that multivariate analysis could be used to
adjust for important confounders.
We expect that over-sampling of providers in the Balti-
more-Washington, D.C. area resulted in data collection
from multiple providers who work in the same clinic. This
clustering of providers may result in correlation of some
variables at the clinic level. As the survey did not ask parti-
cipants to reveal the name or location of their specific clin-
ical sites, we were not able to statistically account for this
clustering. Provider self-report is a sub-optimal method of
assessing prescribing behaviour and adherence with prac-
tice guidelines due to imperfect recall and the possibility
of socially desirable reporting [40].
Use of an Internet-based survey instrument has advan-
tages in this regard. An anonymous, self-administered
survey which providers can complete in private at a
time and place of their choice may minimize this poten-
tial bias. As the proportion of personally invited provi-
ders who completed surveys was lower in our study
than several mail-based surveys of HIV providers
[22,33,41], it is possible that web-based questionnaires
are a less effective strategy for achieving favourable sur-
vey response rates from health care providers than tradi-
tional mailings.
Conclusions
Our analyses suggest that HIV providers are significantly
less likely to recommend antiretroviral therapy at any
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Page 8 of 10CD4+ cell count for patients who engage in any injec-
tion drug use. While many providers would consider
prescribing ART to patients who inject occasionally,
most would defer therapy for patients who inject daily,
even for patients who meet immunologic criteria for
AIDS. Providers with greater HIV care experience and
non-physician providers may be less resistant to pre-
scribing ART in the setting of injection drug use. Efforts
to reduce disparities in ART utilization and HIV treat-
ment effectiveness for IDUs should acknowledge that
many providers may be reluctant to prescribe treatment
for this marginalized patient group.
Additional material
Additional file 1: Copy of provider survey.
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